Clinical Trial News

New pooled analysis in The Lancet shows semaglutide reduces risk of combined CV death or worsening heart failure by 31%, with a 41% lower risk of worsening HF. Semaglutide not approved for heart failure outcomes in the US. Analysis included 3,743 HFpEF patients from four trials.

A study evaluated the effectiveness of a novel composite biologics (UBM/SIS) in laparoscopic inguinal hernia repair (LIHR) compared to a synthetic mesh. The four-year follow-up showed no significant difference in hernia repair effectiveness rates (100% vs 95.45%) and lower incidence of postoperative complications with UBM/SIS. Trial registration: ChiCTR1800020173.

Novavax's 2024-2025 Formula COVID-19 vaccine, NVX-CoV2705, receives EUA from FDA for use in individuals aged 12+ to prevent COVID-19. The vaccine targets JN.1, a 'parent strain' of currently circulating variants, and is available in pre-filled syringes at thousands of locations nationwide. The CDC recommends its use, and it includes Matrix-M adjuvant for enhanced immune response.

Aclarion expands its multi-center CLUE Trial to New Jersey, led by Dr. Justin Kubeck at Ocean Pain and Spine, aiming to assess Nociscan's AI data impact on chronic low back pain treatment plans. Nociscan, Aclarion's SaaS platform, uses biomarkers and AI to identify pain sources in the lumbar spine, aiding physicians in treatment decisions.

Suresh Garimella appointed as U of A president with $810,000 salary. Delta Development Team's blood storage tech saves lives. Journey Venture Studio selects health care entrepreneurs. Ivy Brain Tumor Center tests new brain cancer drug. Tech Launch Arizona sets invention record. Peter Fine leads Banner Health's growth. Boeing, Honeywell launch STEM academy with EVIT.

Inari Medical to present PEERLESS trial data at TCT 2024, comparing FlowTriever system vs. catheter-directed thrombolysis for intermediate-risk pulmonary embolism.

The Government of Canada invested $43 million in 14 new clinical trials to prepare for future health emergencies and advance the life sciences sector, with four trials led by researchers at the RI-MUHC.

A study by Andrew Hantel, MD, and colleagues at Dana-Farber Cancer Institute and 6 other hospitals found that patients from minoritized populations with AML were eligible for 6.8% fewer clinical trials than Non-Hispanic White patients, highlighting the need for more inclusive trial designs.

A phase 2b/3 trial evaluated ensitrelvir's efficacy and safety in asymptomatic SARS-CoV-2 and mild COVID-19 patients. Conducted in Japan, South Korea, and Vietnam, participants were randomized to ensitrelvir 125-mg, 250-mg, or placebo groups. Ensitrelvir showed potential in reducing COVID-19 symptom development/worsening and demonstrated antiviral efficacy with mostly mild to moderate adverse events.

On Aug. 29, 2024, at 6 p.m., 'Health Matters' discusses methamphetamine addiction with Dr. Shawn McNeil, Kevin Murnane, PhD, and Frances Vest, focusing on a psilocybin clinical trial at LSU Health Shreveport. Call 1-800-552-8502 for questions.